Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069692 | 1.00 | — | — | |
| SCHEMBL7027263 | 1.00 | GLA (0.67) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6536452 | 1.00 | GLA (0.67) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL9352555 | 0.97 | — | — | |
| Ethylene Glycol SCHEMBL673538 | 0.92 | GLA (0.59) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Propane SCHEMBL1995071 | 0.92 | GLA (0.59) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30918304 | 0.92 | GLA (0.59) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9058899 | 0.92 | CYP1A2 (0.61) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9131420 | 0.92 | CYP1A2 (0.61) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4350905 | 0.92 | CYP1A2 (0.61) | GLACYP1A2MAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | claimed |
| EP-1689384-A4 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | CONCAT LP (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2011501-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use | Chelator LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1261349-B1 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE | CHELATOR LLC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1689384-A1 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | Concat LP (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-0955044-B1 | Method of inhibiting bacterial or fungal growth using a complexing agent | CHELATOR LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005053674-A1 | COMPLEXES OF CYCLIC POLYAZA CHELATORS WITH CATIONS OF ALKALINE EARTH METALS FOR ENHANCED BIOLOGICAL ACTIVITY | CONCAT LP (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | CONCAT LP, A CALIFORNIA LIMITED PARTNERSHIP (US) | 2005-05-26 | — | — | US | disclosed |
| US-6881732-B2 | Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements | CHELATOR LLC (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1382332-A1 | Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent | Chelator LLC (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | CHELATOR LLC | 2001-11-15 | — | — | US | disclosed |
| US-6288224-B1 | Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylethyl-ethanolamine sulphonate esters as intermediates | NYCOMED SALUTAR, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6264966-B1 | DEODORANTS; THERAPY FOR ORAL DISEASES | CONCAT, LTD. | 2001-07-24 | — | — | US | disclosed |
| US-6165996-A | Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis | CONCAT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6048979-A | CYCLOTETRAMERIZING, CLEAVAGE OF ARYLMETHYL GROUPS TO PREPARE CYCLEN AND DERIVATIVES | NYCOMED SALUTAR, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0955044-A2 | Method of inhibiting bacterial or fungal growth using a complexing agent | CONCAT LTD. (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| CN-1181751-A | Prepn. of N-arylmethyl axiridine derivatives, 1, 4, 7, 10 -Tetraazacyclododecane derivatives obtained therefrom and N -arylmethyl -ethanol -amine sulphonate esters as intermediates | NYCOMED SALUTAR INC (US) | 1998-05-13 | — | — | CN | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041170-A1 | Compounds with chelation affinity and selectivity for first transition series elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury | MPO, LPO, SOD1 | GLA 27/4885CYP1A2 2190/4885MAPK1 3131/4885 |
| US-20050112066-A1 | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity | SLC39A14, CHIA, CA2 | GLA 88/4885CYP1A2 4785/4885MAPK1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.